Fig. 1

Concomitant AHA use at the time of the first canagliflozin claim (N = 4017). Concomitant AHA use was defined based on treatments the patient had available at the time of the first canagliflozin claim (there must have been ≥1 claim for the medication prior to the index date, ≥1 claim for the medication on or after the index date, and no gap of ≥60 days in the medication at the time of the first canagliflozin claim). AHA, antihyperglycemic agent